Publications by authors named "Jane Margetts"

Claim this Profile
N
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
Mairéad G McNamara, Jayne Swain, Zoe Craig, Rohini Sharma, Olusola Faluyi, Jane Margetts

EClinicalMedicine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 and liver cancer: lost patients and larger tumours.
Daniel Geh, Robyn Watson, Gourab Sen, Jeremy J French, John Hammond, Jane Margetts

BMJ Open Gastroenterol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?
Jane Margetts, Laura F Ogle, Stephen L Chan, Anthony W H Chan, K C Allen Chan

Br J Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The use of circulating biomarkers in early clinical trials in patients with cancer.
Manolo D'Arcangelo, Jane Margetts, Alastair Greystoke

Biomark Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Rodryg Ramlau, Michael Thomas, Silvia Novello, Ruth Plummer, Martin Reck, Jane Margetts

Clin Lung Cancer· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Christophe Massard, Jane Margetts, Nadia Amellal, Yvette Drew, Ratislav Bahleda

Invest New Drugs· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
David Jamieson, Kerrie Wilson, Simon Pridgeon, Jane P Margetts, Richard J Edmondson

Clin Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis